Καθηγητής Θεραπευτικής Παθολογίας-Ογκολογίας, Εθνικό & Καποδιστριακό Πανεπιστήμιο Αθηνών, Διευθυντής 2ης Προπαιδευτικής Παθολογικής Κλινικής, Ιατρική Σχολή ΕΚΠΑ «ΑΤΤΙΚΟΝ» Πανεπιστημιακό Νοσοκομείο

Αριστοτέλης Μπάμιας

Aristotelis Bamias, MD, PhD, is Professor at the Medical School, University of Athens, in Greece. He studied Μedicine in the Medical School of the University of Athens and trained in Ιnternal Μedicine and Μedical Οncology in the United Kingdom, at the Hammersmith, Royal Marsden and St Bartholomew’s Ηospitals in London. Professor Bamias successfully completed his thesis at the University of Athens and subsequently obtained a PhD from the University of London, working on the application of monoclonal antibodies to cancer diagnosis and treatment. He served as Lecturer in Medical Oncology at the University of London. He is now a practicing medical oncologist in Greece and is the Director of the 2nd Propaedeutic Department of Internal Medicine of the University of Athens at the ATTIKON University Hospital in Athens.

Professor Bamias was the coordinator of the genito-urinary working group of the Hellenic Cooperative Oncology Group (HECOG) for 10 years and the representative of HECOG at the European Network Gynaecological Oncological Trial Groups (ENGOT) for 3 years. Professor Bamias is a founding member and Chair of the Hellenic Genito-Urinary Cancer Group (HGUCG). He is a member of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) and the Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators.

Professor Bamias is a member of the Royal College of Physicians (MRCP, UK), full member of the European Society for Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO), the European Society of Gynaecological Oncology (ESGO), the European Society of Translational medicine (EUSTM) and a certified member of the Academy of Translational Medicine Professionals (ATMP). He has been member of the ESMO Faculty for Genitourinary Cancer since 2012 and he is currently chairing this group. In this capacity he has been member of the scientific committees of ESMO and EMUC Congresses since 2016, invited faculty in the respective congresses and organized several ESMO educational activities. His main research focus in oncology is urogenital tumours. A member of several international advisory boards, steering committees of international trials and Consensus Groups, he has led numerous national and international, industry-sponsored and academic studies and he has published 270 original papers and reviews in peer-reviewed journals, including the N Engl J Med, Lancet, Lancet Oncology and J Clin Oncol, with more than 11000 citations by other authors and a current h-index of 52.